← Patent-cliff monitor small molecule GAVRETO PRALSETINIB
Loss of exclusivity July 2042 latest FDA-listed patent expiry
Drug detail Brand name GAVRETO Active ingredient PRALSETINIB Strength 100MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval September 2020 Marketing status RX
Listed patents Patent Expires Type 12448366 July 2042 substance 11273160 April 2039 use U-2952 12539303 April 2039 use U-2828 11872192 April 2039 use U-2952 11963958 April 2039 use U-2828 10030005 November 2036 substance, product
Regulatory exclusivity Code Expires ODE-340 December 2027 ODE-341 December 2027 ODE-318 September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.